Harbin Gloria Pharmaceuticals (002437) — Working Capital to Net Assets Ratio
Harbin Gloria Pharmaceuticals (002437) has a Working Capital to Net Assets ratio of 26.6% as of March 2026. Working capital of CN¥639.55 Million (current assets of CN¥1.35 Billion minus current liabilities of CN¥709.56 Million) is measured against net assets of CN¥2.41 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Harbin Gloria Pharmaceuticals financial flexibility index to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Harbin Gloria Pharmaceuticals Working Capital to Net Assets (2007–2025)
This chart shows how Harbin Gloria Pharmaceuticals's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 26.6%, reflecting working capital of CN¥639.55 Million against net assets of CN¥2.41 Billion CNY. See 002437 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Harbin Gloria Pharmaceuticals (2007–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Harbin Gloria Pharmaceuticals from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Harbin Gloria Pharmaceuticals stock valuation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 22.6% | CN¥521.00 Million | CN¥2.31 Billion | CN¥1.32 Billion | CN¥797.85 Million | ▲ +19.8 pp |
| 2024 | 2.7% | CN¥54.16 Million | CN¥1.97 Billion | CN¥877.19 Million | CN¥823.03 Million | ▲ +17.8 pp |
| 2023 | -15.1% | CN¥-257.78 Million | CN¥1.71 Billion | CN¥1.15 Billion | CN¥1.41 Billion | ▲ +15.5 pp |
| 2022 | -30.5% | CN¥-520.11 Million | CN¥1.70 Billion | CN¥1.82 Billion | CN¥2.34 Billion | ▼ -6.4 pp |
| 2021 | -24.1% | CN¥-477.90 Million | CN¥1.98 Billion | CN¥2.20 Billion | CN¥2.68 Billion | ▲ +14.9 pp |
| 2020 | -39.1% | CN¥-755.39 Million | CN¥1.93 Billion | CN¥1.79 Billion | CN¥2.54 Billion | ▲ +59.3 pp |
| 2019 | -98.4% | CN¥-1.56 Billion | CN¥1.59 Billion | CN¥3.20 Billion | CN¥4.77 Billion | ▼ -71.0 pp |
| 2018 | -27.3% | CN¥-1.20 Billion | CN¥4.39 Billion | CN¥2.82 Billion | CN¥4.02 Billion | ▲ +1.9 pp |
| 2017 | -29.2% | CN¥-1.24 Billion | CN¥4.25 Billion | CN¥2.03 Billion | CN¥3.27 Billion | ▲ +8.0 pp |
| 2016 | -37.3% | CN¥-1.51 Billion | CN¥4.05 Billion | CN¥2.01 Billion | CN¥3.52 Billion | ▲ +18.6 pp |
| 2015 | -55.8% | CN¥-1.94 Billion | CN¥3.47 Billion | CN¥2.06 Billion | CN¥4.00 Billion | ▼ -58.9 pp |
| 2014 | 3.1% | CN¥94.99 Million | CN¥3.10 Billion | CN¥1.53 Billion | CN¥1.44 Billion | ▼ -40.6 pp |
| 2013 | 43.6% | CN¥1.08 Billion | CN¥2.48 Billion | CN¥1.53 Billion | CN¥446.25 Million | ▼ -29.2 pp |
| 2012 | 72.9% | CN¥1.72 Billion | CN¥2.36 Billion | CN¥1.91 Billion | CN¥186.79 Million | ▼ -6.2 pp |
| 2011 | 79.1% | CN¥1.74 Billion | CN¥2.20 Billion | CN¥1.82 Billion | CN¥81.27 Million | ▼ -4.0 pp |
| 2010 | 83.1% | CN¥1.76 Billion | CN¥2.12 Billion | CN¥1.84 Billion | CN¥73.73 Million | ▲ +56.5 pp |
| 2009 | 26.6% | CN¥76.45 Million | CN¥287.53 Million | CN¥231.40 Million | CN¥154.95 Million | ▼ -14.5 pp |
| 2008 | 41.1% | CN¥79.83 Million | CN¥194.04 Million | CN¥164.71 Million | CN¥84.89 Million | ▲ +14.4 pp |
| 2007 | 26.7% | CN¥36.95 Million | CN¥138.36 Million | CN¥112.73 Million | CN¥75.79 Million | — |